Table 10.
Estimated Economic Impact of Combined Oral Contraceptives due to Increased Incidence of Systemic Lupus Erythematosus.
| Women of reproductive age | Number on the pill | Low incidence | High incidence | ||
|---|---|---|---|---|---|
| 61,000,000 | 9,699,000 | 0.000065 | 0.0001065 | ||
| Estimated women on the pill at risk | 630 | 1,028 | |||
| Adjusted estimate | 914 | 1,491 | 1.45 | Low RR | |
| Adjusted estimate | 1,589 | 2,591 | 2.52 | High RR | |
| Excess cases | 284 | 463 | Low RR | ||
| Excess cases | 958 | 1,563 | High RR | ||
| Annual cost per patient with systemic lupus erythematosus | US$21,535 | ||||
| Estimated annual costs | US$6,109,388 | US$9,963,002 | Low RR | ||
| Estimated annual costs | US$20,636,155 | US$33,652,807 | High RR | ||
Note: RR = relative risk.